key: cord-0999291-xlib4x5l authors: NIR, Omer; SCHWARTZ, Anat; TOUSSIA-COHEN, Shlomi; LEIBOVITCH, Leah; STRAUSS, Tzipi; ASRAF, Keren; DOOLMAN, Ram; SHARABI, Ms. Sivan; COHEN, Carmit; LUSTIG, Yaniv; REGEV-YOCHAY, Gili; YINON, Yoav title: Maternal-Neonatal Transfer of SARS CoV-2 IgG Antibodies among Parturient Women Treated with BNT162b2 mRNA Vaccine during Pregnancy date: 2021-09-20 journal: Am J Obstet Gynecol MFM DOI: 10.1016/j.ajogmf.2021.100492 sha: 4704be37ff07366eb59bd45df662a7d04effd253 doc_id: 999291 cord_uid: xlib4x5l Background The exclusion of pregnant women from COVID-19 mRNA vaccine trials raised hesitancy regarding the benefit of vaccination of pregnant women, hence little is known about the vaccine's efficacy in this population. Objective To determine the maternal-neonatal transplacental transfer of SARS CoV-2 antibodies among vaccinated parturient women. A control group of COVID 19 recovered patients was included in order to compare IgG levels between vaccinated and recovered patients. Study Design A prospective cohort study in a single tertiary medical center in Israel between February and March 2021; parturient women who had been vaccinated with BNT162B2 mRNA vaccine during pregnancy were included and compared to COVID-19 recovered parturient women. SARS CoV-2 IgG antibodies were measured in maternal and cord sera, dried blood spot samples taken from newborns, and breast-milk samples. The primary outcome was to determine whether neonatal cord and dried blood spot samples were positive for SARS CoV-2 antibodies and to evaluate transfer ratio defined as cord blood IgG divided by maternal IgG levels. Results The study included 64 vaccinated parturient women and 11 parturient women who had COVID-19 disease during pregnancy. All maternal blood sera samples and 98.3% of cord blood sera samples were positive for SARS Cov-2 IgG with median concentrations of 26.1 (IQR 22.0;39.7) and 20.2 (IQR 12.7;29.0) respectively. Similarly, 96.4% of neonatal blood spot samples and all breast milk samples were positive for SARS CoV-2 IgG with median concentrations of 11.0 (IQR 7.2;12.8) and 4.9 (IQR 3.8;6.0), respectively. There was a significant positive correlation between maternal serum levels of SARS Cov-2 IgG and cord blood (R=0.483, p=0.0001), neonatal blood spot (R=0.515, p=0.004), and breast milk levels (R=0.396, p=0.005) of SARS CoV-2 IgG. The median placental transfer ratio of SARS-COV-2 IgG was 0.77. Comparison of vaccinated with recovered COVID-19 patients revealed significantly higher SARS CoV-2 IgG levels in maternal serum and cord blood among vaccinated women (p<0.0001). Conclusion(s) Our study demonstrated efficient transfer of SARS CoV-2 IgG across the placenta from women vaccinated with BNT162b2 mRNA vaccine during pregnancy to their neonates with positive correlation between maternal serum and cord blood antibody concentrations. In addition to maternal protection against COVID-19, the vaccine may also provide neonatal humoral immunity. antibodies to their neonates. Short title: Maternal-neonatal SARS CoV-2 IgG antibodies transfer following vaccination of pregnant women. A. Why was this study conducted?  Pregnant women were excluded from initial trials of SARS CoV-2 vaccine, hence little is known about its efficacy in this population.  It is known that maternal-neonatal transfer of antibodies exists both transplacentally and via lactation. Study Design: A prospective cohort study in a single tertiary medical center in Israel between February and March 2021; parturient women who had been vaccinated with BNT162B2 mRNA vaccine during pregnancy were included and compared to COVID-19 recovered parturient women. SARS CoV-2 IgG antibodies were measured in maternal and cord sera, dried blood spot samples taken from newborns, and breast-milk samples. The primary outcome was to determine whether neonatal cord and dried blood spot samples were positive for SARS CoV-2 antibodies and to evaluate transfer ratio defined as cord blood IgG divided by maternal IgG levels. Our study demonstrated efficient transfer of SARS CoV-2 IgG across the placenta from women vaccinated with BNT162b2 mRNA vaccine during pregnancy to their neonates with positive correlation between maternal serum and cord blood antibody concentrations. In addition to maternal protection against COVID-19, the vaccine may also provide neonatal humoral immunity. Transplacental passage of maternal derived SARS CoV-2 antibodies among seropositive women who were infected with COVID-19 has been described, showing that cord blood IgG antibody concentrations were directly associated with maternal antibody concentrations and with time elapsed from maternal infection to delivery [9] [10] [11] [12] . In addition to maternal protection against COVID-19 following vaccination, the potential benefit of transplacental and lactation passage of antibodies is of immense importance, as it may provide infants with protection against COVID-19 at a phase in which their humoral response is still inefficient 13-19 . Such findings may play an additional key consideration in deciding whether to vaccinate pregnant women. Our aim was to assess the transfer of maternal antibodies among infants born to women vaccinated with BNT6b2 mRNA vaccine during pregnancy by measuring SARS CoV-2 antibodies in maternal and cord sera, infant blood spot sample, and breast-milk during post-partum hospitalization. A prospective cohort study of parturient women who had been vaccinated with BNT162b2 mRNA vaccine during pregnancy and COVID-19 recovered parturient women who were admitted for delivery at a single tertiary medical center between February and March 2021. Inclusion criteria included pregnant women aged 18 years or older who had received two doses of BNT162b2 mRNA covid-19 vaccine at least 14 days prior to delivery. COVID-19 recovered women with previous documented positive polymerase-chain-reaction (PCR) test for SARS CoV-2 served as a control group; patients were defined as recovered if they were asymptomatic for 3 days or more after 10 days had elapsed from the initial positive PCR test for SARS CoV-2. Documentation of a positive PCR test during the acute phase of infection was required, as well as a signed form by the Ministry of Health stating that the patients were defined as recovered. Eligible women were offered to participate upon admittance to the delivery room or operating room in cases of elective Cesarean delivery. Data regarding general medical history and pregnancy outcomes were collected. Maternal blood samples were obtained upon admittance, and cord blood samples were taken immediately post-partum. Serum samples were centrifuged at 4000 G for 4 min in room temperature. The samples were tested for SARS-COV-2 RBD IgG using the commercial automatic Descriptive statistics were used to assess the demographic and clinical characteristics of the participants and are presented as mean ± standard deviation (SD) or median and interquartile ranges (IQR( as appropriate. SARS CoV-2 antibody levels were analyzed and correlation between maternal concentrations and cord, neonatal, and breast milk concentrations was assessed. The study included 64 parturient women who had been vaccinated with two doses of BNT162b2 mRNA vaccine and 11 parturient women who had COVID-19 disease during pregnancy. The demographic and clinical characteristics are presented in Table 1 (Table 2) . There was a significant positive correlation between maternal serum levels of SARS Cov-2 IgG and cord blood (R=0.483, p=0.0001), neonatal blood spot (R=0.515, p=0.004), and breast milk levels (R=0.396, p=0.005) of SARS CoV-2 IgG (Figure 1 A-C) . The median placental transfer ratio of SARS-COV-2 IgG was 0.77. We observed a negative significant correlation between time elapsed since the second dose of the vaccine and maternal serum IgG levels (r=-0.386, p=0.003), but correlation with cord blood IgG levels was not as clear (r=0.159, p=0.14) (Figure 2 ). Comparison of vaccinated to recovered COVID-19 patients revealed significantly higher SARS CoV-2 IgG levels in maternal and cord blood samples among vaccinated women (p<0.0001) ( Table 2) . Principal Findings: Our study demonstrated efficient transfer of SARS CoV-2 IgG across the placenta from women who were vaccinated with BNT162b2 mRNA vaccine during pregnancy to their neonates with positive correlation between maternal serum and cord blood antibody concentrations. Neonatal blood spot as well as breast milk samples of vaccinated parturient were also positive for SARS CoV-2 IgG. Vaccine induced maternal serum and cord blood antibody titers were higher than those found in recovered COVID-19 patients. The presence of neonatal SARS CoV-2 antibodies after maternal vaccination indicates that in addition to maternal protection against COVID-19, the BNT162b2 mRNA vaccine may also provide neonatal immunity while humoral response is still inefficient. Such findings may play an additional key consideration in deciding whether to vaccinate pregnant women, especially with the increased maternal morbidity and mortality associated with COVID-19 disease in pregnancy. In a previous study on parturient women who had COVID-19 disease during pregnancy, maternal SARS-CoV-2 IgG antibodies IgG were transferred across the placenta in 87% of patients. In addition, cord blood antibody levels were correlated with maternal antibody concentrations as well as with duration between onset of infection and delivery 9 . In our study, cord and neonatal blood spot levels of antibodies were significantly higher among infants of vaccinated parturient women compared to recovered COVID-19 disease. In line with our results, a recent study by Gray et al. has also shown greater response among vaccinated women compared to recovered patients 22 . Yet, it is unclear whether vaccination confers better neonatal immunity compared to maternal infection with SARS CoV-2 during pregnancy. Of note, the time elapsed between disease or vaccination and delivery was significantly longer among the COVID-19 recovered patients, which could also explain the difference we found in cord and neonatal blood antibody levels between the two groups. The optimal timing of maternal vaccination to achieve maximal protection of the newborn is still unknown. Mithal et al. have recently shown that the antibody transfer ratio seems to increase with latency from vaccination, suggesting that earlier vaccination may produce a greater infant immunity 23 . Studies on other vaccinations found that placental transfer ratios increased when the time between maternal infection and delivery was longer 24 . Other vaccinations in pregnancy such as Tdap immunization are given between 27 and 36 weeks of gestation according to the ACOG and CDC recommendations 25 . However, some studies have indicated that Tdap vaccine might be more effective when administered during the second trimester of pregnancy 26 . In the current study, all participants were vaccinated in the third trimester at a mean gestational age of 33.5, but no correlation between time from vaccination and cord blood antibody levels was demonstrated. However, a recent study including 20 parturient women who received mRNA COVID-19 vaccine found cord blood antibody concentrations to be correlated with time since vaccination 27 . The placental transfer ratio reported in the aforementioned study was 0.34, which is lower compared to a ratio of 0.77 found in our study. This difference may be attributed to the longer interval of vaccination to delivery in our cohort (21.7 vs 11 days). Since transplacental transfer begins at around 17 weeks of gestation increasing exponentially as gestation advances, maternal vaccination in the early second trimester might be optimal for newborn protection 28 . Data derived from other vaccines indicate that transplacentally acquired antibodies usually decline by the second month of life, and the protective efficacy is expected to be reduced at the age of 6 to 12 months. parturient women was also included using the same methods. This study has several limitations: first, lack of long-term follow up and serial sample collection. Second, since all women were vaccinated during a short window of the third trimester (33.5±3 weeks) we cannot determine the most beneficial time to vaccinate. As the vaccine was a new treatment at the time this study was conducted, women vaccinated during first or second trimester were not included since they haven't delivered by the time the study was completed. Furthermore, this study did not prove clinical efficacy in protecting infants from COVID-19. Neither the degree of neonatal protection against SARS CoV-2 nor the length of time that such potential protection lasts from delivery can be assessed from this study alone, and further large-scale, long-term research is required to elucidate this issue. We have demonstrated that parturient women who had been vaccinated with a full 2-dose BNT6b2 mRNA vaccine prior to delivery transfer SARS CoV-2 IgG antibodies to their infants with evidence of antibodies in cord blood, neonatal blood spot samples and breast milk samples. These data show an additional benefit of the novel BNT6b2 mRNA vaccine in potentially providing protection to newborns in a sensitive period during which their humoral protection is ineffective. Further research is needed to determine the optimal time for vaccination during pregnancy with respect to newborn immunity, and whether transplacentally transferred SARS CoV-2 antibodies provide clinically and long lasting infant protection. Gestational hypertensive disease comprised of pregnancy induced hypertension and preeclampsia toxemia Data are presented as n (%) or mean (±SD) where appropriate Figure 1A Association between maternal serum and neonatal cord SARS-CoV-2 specific IgG. Figure 1B . Association between maternal serum and neonatal dried blood-spot specific SARS-CoV-2 IgG. Figure 1C . Association between maternal serum and breastmilk SARS-CoV-2 specific IgG Figure 2 Association between time elapsed from vaccination and maternal and cord blood IgG levels Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status -United States BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting Safety and Efficacy of the BNT162b2 mRNA Covid-19 Pregnancy, breastfeeding and the SARS-CoV-2 vaccine: an ethics-based framework for shared decision-making Vaccinating Pregnant and Lactating Patients Against COVID-19 COVID-19 vaccines, pregnancy and breastfeeding Israel Society of Obstetrics and Gynecology -COVID 19 Vaccination Assessment of Maternal and Neonatal Cord Blood SARS-CoV-2 Antibodies and Placental Transfer Ratios Transplacental transmission of SARS-CoV-2 infection Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn Antibodies in Infants Born to Mothers With COVID-19 Pneumonia Van de Perre P. Transfer of antibody via mother's milk. Vaccine Efficiency of placental transfer of vaccine-elicited antibodies relative to prenatal Tdap vaccination status Safety and immunogenicity of three seasonal inactivated influenza vaccines among pregnant women and antibody persistence in their infants The Impact of IgG transplacental transfer on early life immunity Maternal immunization: Optimizing protection for the mother and infant Breastfeeding provides passive and likely long-lasting active immunity Perspectives on immunoglobulins in colostrum and milk Testing IgG antibodies against the RBD of SARS-CoV-2 is sufficient and necessary for COVID-19 diagnosis Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation. EClinicalMedicine Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study Cord blood antibodies following maternal coronavirus disease 2019 vaccination during pregnancy Committee Opinion No. 718: Update on Immunization and Pregnancy: Tetanus, Diphtheria, and Pertussis Vaccination Maternal Immunization Earlier in Pregnancy Maximizes Antibody Transfer and Expected Infant Seropositivity Against Pertussis Efficient maternofetal transplacental transfer of anti-SARS-CoV-2 spike antibodies after antenatal SARS-CoV-2 BNT162b2 mRNA vaccination Can We Protect Pregnant Women and Young Infants From COVID-19 Through Maternal Immunization? JAMA Pediatr COVID-19 vaccine response in pregnant and lactating women: a cohort study